Categorynews

Ocular Therapeutix™ Reports Election of Leslie Williams to Board of Directors

March 25, 2019 Off By BusinessWire

BEDFORD, Mass.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24OCUL&src=ctag" target="_blank"gt;$OCULlt;/agt; lt;a href="https://twitter.com/hashtag/OCUTX?src=hash" target="_blank"gt;#OCUTXlt;/agt;–Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company
focused on the formulation, development, and commercialization of
innovative therapies for diseases and conditions of the eye, today
announced the election of Leslie J. Williams to the Board of Directors
of the Company.

“We are very pleased to announce that Leslie is joining our Board,” said
Antony Mattessich, President and Chief Executive Officer. “As we focus
on our goal of becoming a fully integrated commercial company, we are
excited to be adding someone of Leslie’s quality and experience to our
board.”

“I am delighted to be joining the Ocular board as the Company embarks
upon the commercial launch of DEXTENZA,” said Ms. Williams. “Ocular is
solidly positioned to potentially transform ophthalmic drug delivery and
I look forward to contributing to the growth and expansion of this
innovative Company.”

Ms. Williams is the founder of the biotechnology company ImmusanT, Inc.
and has served as a member of its board of directors and as its
President and Chief Executive Officer since its inception in December
2010. Prior to founding ImmusanT, Ms. Williams served as the President
and Chief Executive Officer and as a member of the board of directors of
Ventaira Pharmaceuticals, Inc., a specialty pharmaceutical company. Ms.
Williams was also a venture partner at Battelle Ventures, an early stage
venture capital fund, and served on the boards of directors of Hepregen
Inc., a company engaged in the development and marketing of proprietary
drug screening products, and of CDI Bioscience, Inc., a cell line
engineering and contract manufacturing company. Ms. Williams is a member
of the board of advisors of Life Science Cares, the executive board of
the University of Iowa College of Pharmacy and of the editorial advisory
boards of Life Science Leader and the Journal of Advanced Therapies and
Medical Innovation Sciences. Ms. Williams received a B.S. in Nursing
from the University of Iowa and a M.B.A. from the Washington University
John Olin School of Business.

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the
formulation, development, and commercialization of innovative therapies
for diseases and conditions of the eye using its proprietary
bioresorbable hydrogel-based formulation technology. Ocular
Therapeutix’s first commercial drug product, DEXTENZA^®, is
FDA-approved for the treatment of ocular pain following ophthalmic
surgery. OTX-TP (intracanalicular travoprost insert) is an
intracanalicular insert in Phase 3 clinical development for the
reduction of intraocular pressure in patients with primary open-angle
glaucoma and ocular hypertension. The Company’s earlier stage assets
include OTX-TIC, an extended-delivery intracameral travoprost implant
for the reduction of intraocular pressure in patients with glaucoma and
ocular hypertension, as well as sustained release intravitreal implants
for the treatment of retinal diseases. These intravitreal implants
include OTX-TKI, containing a tyrosine kinase inhibitor (TKI), and, in
collaboration with Regeneron, OTX-IVT, an extended-delivery
protein-based anti-vascular endothelial growth factor (VEGF) trap.
Ocular Therapeutix’s first product, ReSure^® Sealant, is
FDA-approved to seal corneal incisions following cataract surgery.

Forward Looking Statements

Any statements in this press release about future expectations, plans,
and prospects for the Company, the commercialization of DEXTENZA^®,
ReSure Sealant or any of the Company’s product candidates, including the
anticipated commercial launch of, and receipt of reimbursement codes
for, DEXTENZA; the development and regulatory status of the Company’s
product candidates, such as the Company’s regulatory submissions for and
the timing and conduct of, or implications of results from, clinical
trials of DEXTENZA for the treatment of post-surgical ocular
inflammation and the prospects for approvability of DEXTENZA for
post-surgical ocular inflammation or any other indications, OTX-TP for
the treatment of primary open-angle glaucoma and ocular hypertension,
OTX-TIC for the treatment of primary open-angle glaucoma and ocular
hypertension, OTX-TKI for the treatment of retinal diseases including
wet AMD, and OTX-IVT as an extended-delivery formulation of the VEGF
trap aflibercept for the treatment of retinal diseases including wet
AMD; the Company’s post-approval studies of ReSure^® Sealant
and the Company’s ongoing communications with the U.S. Food and Drug
Administration regarding the warning letter the Company received
regarding ReSure Sealant; the ongoing development of the Company’s
extended-delivery hydrogel depot technology; the potential utility of
any of the Company’s product candidates; the potential benefits and
future operation of the collaboration with Regeneron Pharmaceuticals,
including any potential future payments thereunder; the sufficiency of
the Company’s cash resources and other statements containing the words
“anticipate,” “believe,” “estimate,” “expect,” “intend”, “goal,” “may”,
“might,” “plan,” “predict,” “project,” “target,” “potential,” “will,”
“would,” “could,” “should,” “continue,” and similar expressions,
constitute forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those indicated by such forward-looking statements as a
result of various important factors. Such forward-looking statements
involve substantial risks and uncertainties that could cause the
Company’s clinical development programs, future results, performance or
achievements to differ significantly from those expressed or implied by
the forward-looking statements. Such risks and uncertainties include,
among others, those related to the timing and costs involved in
commercializing DEXTENZA, ReSure Sealant or any product candidate that
receives regulatory approval, including the conduct of post-approval
studies, the ability to retain regulatory approval of DEXTENZA, ReSure
Sealant or any product candidate that receives regulatory approval, the
ability to obtain reimbursement codes for DEXTENZA, the initiation,
timing and conduct of clinical trials, availability of data from
clinical trials and expectations for regulatory submissions and
approvals, the Company’s scientific approach and general development
progress, the availability or commercial potential of the Company’s
product candidates, the sufficiency of cash resources, the Company’s
existing indebtedness, the ability of the Company’s creditors to
accelerate the maturity of such indebtedness upon the occurrence of
certain events of default, the outcome of the Company’s ongoing legal
proceedings and need for additional financing or other actions and other
factors discussed in the “Risk Factors” section contained in the
Company’s quarterly and annual reports on file with the Securities and
Exchange Commission. In addition, the forward-looking statements
included in this press release represent the Company’s views as of the
date of this release. The Company anticipates that subsequent events and
developments will cause the Company’s views to change. However, while
the Company may elect to update these forward-looking statements at some
point in the future, the Company specifically disclaims any obligation
to do so except as required by law. These forward-looking statements
should not be relied upon as representing the Company’s views as of any
date subsequent to the date of this release.